Sanford C. Bernstein set a €114.00 ($132.56) price target on Merck KGaA (FRA:MRK) in a report released on Thursday, Borsen Zeitung reports. The brokerage currently has a neutral rating on the healthcare company’s stock.

A number of other equities analysts have also recently weighed in on MRK. DZ Bank reissued a buy rating on shares of Merck KGaA in a research report on Wednesday, August 14th. Warburg Research set a €103.00 ($119.77) price target on shares of Merck KGaA and gave the stock a neutral rating in a research report on Tuesday, July 30th. Credit Suisse Group set a €110.00 ($127.91) price target on shares of Merck KGaA and gave the stock a buy rating in a research report on Friday, September 6th. Bank of America set a €110.00 ($127.91) price target on shares of Merck KGaA and gave the stock a neutral rating in a research report on Friday, September 13th. Finally, Barclays set a €85.00 ($98.84) price target on shares of Merck KGaA and gave the stock a sell rating in a research report on Tuesday, November 12th. One analyst has rated the stock with a sell rating, twelve have given a hold rating and five have given a buy rating to the stock. The stock has an average rating of Hold and an average target price of €101.88 ($118.47).

FRA:MRK traded up €1.85 ($2.15) on Thursday, reaching €108.00 ($125.58). The stock had a trading volume of 770,765 shares. The company has a 50-day moving average of €105.44 and a 200 day moving average of €96.92. Merck KGaA has a 12-month low of €76.60 ($89.07) and a 12-month high of €115.00 ($133.72).

About Merck KGaA

MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.

Recommended Story: How liquidity affects the bid-ask spread

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.